A 2016 AAAAI position statement recommended routine evaluation of beta-lactam allergies due to the burden of pervasive mislabeled allergies. This quality improvement study implemented strategies to expedite evaluation at Rady Children's Hospital. METHODS: A real-time list of inpatients with beta-lactam allergies, Best Practice Advisory and automatic referral was created in EPIC. Pharmacy staff documented reactions using a standardized Smartform aimed at distinguishing reaction types (i.e., immediate vs delayed). The Smartform was also used to document reactions of outpatients in Allergy Clinic. Skin testing was performed for first-day reactions, a raised and mobile rash, or by family request. Children with negative skin testing or with non-severe delayed reactions were given graded challenges. RESULTS: 118 patients (15 months to 24 years) were interviewed over 4 months. 34 were evaluated in clinic. 11 (32%) had skin testing. 2 skin tests were positive, and 3 skin tests were incomplete due to discomfort; however, the part performed was negative and the patients passed challenges. The time interval between reaction and testing ranged from 1 month to 14 years. There were no adverse reactions, including during the week following challenge. 32 (94%) of patients evaluated in clinic, and 100% of those offered the challenge, passed. Of 84 admitted patients, 36 (43%) had history that qualified them for skin testing (43%). CONCLUSIONS: This project adapted EPIC tools to expedite evaluation of beta-lactam allergies. Our results suggest that skin testing may not be necessary for the majority of children labeled with a beta-lactam allergy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.